Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERIODS: Tirzepatide in PCOS with Overweight or Obesity
NCT07326111Phase 4Recruiting
- Sponsor
- University of Bonn
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tirzepatide in polycystic ovary syndrome (PCOS) (2 arms), sponsored by University of Bonn. Primary endpoint: Improvement of ovarian dysfunction as defined by menstrual irregularity at 72 weeks. Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT07326111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326111.